EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, 4d pharma's enterprise value is £24.48 Mil.
4d pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2021 was £0.52 Mil. Therefore, 4d pharma's EV-to-Revenue for today is 46.89.
The historical rank and industry rank for 4d pharma's EV-to-Revenue or its related term are showing as below:
LSE:DDDD's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.985 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-06-05), 4d pharma's stock price is £0.1666.
4d pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 was £0.00. Therefore, 4d pharma's PS Ratio for today is 55.53.
4d pharma EV-to-Revenue Historical Data
The historical data trend for 4d pharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of 4d pharma's EV-to-Revenue
For the Biotechnology subindustry, 4d pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4d pharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4d pharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where 4d pharma's EV-to-Revenue falls into.
4d pharma's current Enterprise Value is £24.48 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 4d pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2021 was £0.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4d pharma's share price for today is £0.1666.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2021 was £0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4d pharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of 4d pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:DDDD has been successfully added to your 